ArticleInternational cancer conference journal2025
A case of zolbetuximab-induced protein-losing gastroenteropathy in a patient with advanced gastric cancer.
Article in International cancer conference journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical implications of zolbetuximab-associated hypoalbuminemia in CLDN18.2-positive gastric or gastroesophageal junction cancer.ESMO gastrointestinal oncology · 2026Article
- Safety signals of zolbetuximab in gastric or gastroesophageal junction adenocarcinoma: a comprehensive analysis of the FDA adverse event reporting system (FAERS) data.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zolbetuximab is a monoclonal antibody targeting Claudin 18.2 that has been approved for the treatment of advanced gastric cancer in Japan. Zolbetuximab has its anticancer effects through a variety of mechanisms, including antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Previous studies have identified edema and hypoalbuminemia as adverse events associated with zolbetuximab treatment although the mechanisms underlying these effects remain unclear. In this report, we present a case of zolbetuximab-inducing protein-losing gastroenteropathy in a patient with advanced gastric cancer. This case demonstrated protein leakage from the upper gastrointestinal tract, confirmed through protein leakage scintigraphy. This finding could provide the mechanisms of zolbetuximab-induced edema and hypoalbuminemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.